InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
LivaNova is a global medical technology company built on decades of experience and...
LivaNova is a global medical technology company...
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical com...
Founded in Lyon, France in 2004, ERYTECH is a c...
Proteostasis Therapeutics, Inc. is an innovative biopharmaceutical company committ...
Proteostasis Therapeutics, Inc. is an innovativ...
Founded 20 years ago, Seattle Genetics was built on a foundation of scientific inn...
Founded 20 years ago, Seattle Genetics was buil...
Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company ...
Rocket Pharmaceuticals, Inc. is an emerging, cl...
We are committed to advancing the treatment of eye conditions such as keratoconus ...
We are committed to advancing the treatment of ...
We are a biotechnology company developing novel immunotherapy treatments for cance...
We are a biotechnology company developing novel...
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company develop...
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stag...
Based in South San Francisco, we are a clinical-stage biotechnology company commit...
Based in South San Francisco, we are a clinical...
Viela is dedicated to the development and commercialization of novel, life-changin...
Viela is dedicated to the development and comme...
Join the National Investor Network and get the latest information with your interests in mind.